Skip to main content
logo
Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.370
+0.060 (1.39%)
At close: Apr 2, 2026, 4:00 PM EDT
4.450
+0.080 (1.83%)
After-hours: Apr 2, 2026, 7:49 PM EDT

Taysha Gene Therapies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
9.778.3315.452.5-
Revenue Growth (YoY)
17.28%-46.07%517.55%--
Gross Profit
9.778.3315.452.5-
Selling, General & Admin
33.8728.9530.0537.3641.32
Research & Development
86.46656.7891.17131.94
Other Operating Expenses
-4.841.0736.42-
Total Operating Expenses
120.2799.7987.89164.95173.27
Operating Income
-110.5-91.46-72.44-162.45-173.27
Interest Income
9.226.943.570.250.17
Interest Expense
-0.06-0.1-5-3.8-1.43
Other Non-Operating Income (Expense)
-7.66-4.68-37.7-0.02-
Total Non-Operating Income (Expense)
1.52.16-39.13-3.57-1.26
Pretax Income
-109-89.3-111.57-166.01-174.52
Net Income
-109-89.3-111.57-166.01-174.52
Net Income to Common
-109-89.3-111.57-166.01-174.52
Shares Outstanding (Basic)
3202501164438
Shares Outstanding (Diluted)
3202501164438
Shares Change (YoY)
27.82%115.41%164.20%16.74%113.13%
EPS (Basic)
-0.34-0.36-0.96-3.78-4.64
EPS (Diluted)
-0.34-0.36-0.96-3.78-4.64
Shares Outstanding
285.05204.94186.9663.2138.47
Free Cash Flow
-93.83-81.6-76.89-109.01-132.35
Free Cash Flow Per Share
-0.29-0.33-0.66-2.48-3.52
Gross Margin
100.00%100.00%100.00%100.00%-
Operating Margin
-1130.65%-1097.55%-468.83%-6492.69%-
Profit Margin
-1115.27%-1071.62%-722.06%-6635.25%-
FCF Margin
-960.07%-979.23%-497.62%-4356.87%-
EBITDA
-109.35-90.21-71.07-161.28-172.78
EBITDA Margin
-1118.93%-1082.61%-459.96%-6445.84%-
EBIT
-110.5-91.46-72.44-162.45-173.27
EBIT Margin
-1130.65%-1097.55%-468.83%-6492.69%-
Updated Mar 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q